Trazodone for Sleep: A Patient's Plain-English Guide to Low-Dose Use

Trazodone is an unusual medical success story. It was approved for depression in 1981, was largely displaced from that role by SSRIs in the 1990s, and then quietly became one of the most prescribed sleep aids in the country because clinicians discovered something the FDA never formally endorsed: in small doses, it reliably puts people to sleep.

That informal transition happened because trazodone does something few sleep medications do. It is not habit-forming, not controlled, not expensive, and it carries a different side-effect signature than benzodiazepines or Z-drugs. For patients whose insomnia is tangled up with anxiety or depression, it serves two needs at once.

But off-label widespread use also means that many patients taking it have never received a thorough explanation of how it actually works at sleep doses, what the evidence base really says, and what the side effects are that no one is asking about. This page addresses all of that.

What This Page Covers

• Why trazodone at 25 to 100 mg produces sleep effects that differ from antidepressant dosing
• The receptor mechanisms at low doses
• What the clinical evidence shows, including what it does not show
• Standard dosing protocols and timing
• The side effects most patients never mention but should
• Who is and is not a good candidate
• How continuous medication management catches what single appointments miss

Trazodone Was Never Approved for Insomnia

This is not a minor detail. Trazodone was approved by the FDA in 1981 as an antidepressant at doses of 150 mg per day in divided doses, with doses up to 400 mg for outpatients and 600 mg for inpatients. Its use for insomnia at doses of 25 to 100 mg has no FDA-approved indication.

A 2025 study using nationally representative U.S. data estimated that approximately 24 million trazodone prescriptions were filled in 2019, with at least 85% written for off-label indications, primarily insomnia. It ranks among the most widely prescribed sleep aids in the United States.

The American Academy of Sleep Medicine’s clinical practice guidelines specifically state that trazodone should not be used as a first-line treatment for sleep-onset or sleep-maintenance insomnia, citing insufficient clinical evidence to justify that role. Cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment, followed by FDA-approved pharmacological options when medication is warranted.

Why does trazodone get prescribed so widely then? Because in practice, CBT-I has access barriers. FDA-approved sleep medications have side effects and scheduling concerns of their own. And trazodone, used judiciously, addresses a real clinical need for many patients.

How Low-Dose Trazodone Works for Sleep

Trazodone is classified as a serotonin antagonist and reuptake inhibitor (SARI). At antidepressant doses, its serotonin transporter blockade and 5-HT2 antagonism together produce the mood-stabilizing effect. At lower doses, serotonin transporter occupancy is minimal.

At doses of 25 to 100 mg, trazodone’s sleep benefit comes primarily from blockade of three receptor types: the 5-HT2A serotonin receptor, the histamine H1 receptor, and the alpha-1 adrenergic receptor. All three of these receptors are involved in maintaining wakefulness and arousal. Blocking them produces sedation.

Low-dose trazodone induces and maintains sleep without causing tolerance at therapeutic doses, partly because of its short half-life of 3 to 6 hours at sleep doses. A drug with a 3 to 6 hour half-life taken at bedtime will have largely cleared by morning, which limits daytime carryover compared to longer-acting hypnotics. This pharmacokinetic property is one reason prescribers prefer it for patients who cannot tolerate next-day sedation from other options.

At doses above 100 mg, serotonin reuptake inhibition begins to contribute meaningfully, shifting trazodone’s profile toward antidepressant action. For purely sleep-focused use, most prescribers try to remain under 100 mg.

What the Evidence Shows

A systematic review of 45 studies of trazodone for insomnia found that 95.5% of studies concluded it was effective. However, the evidence quality is moderate. Many studies involved depressed patients for whom trazodone provided secondary sleep benefit. Studies in non-depressed primary insomnia patients are fewer.

The landmark RCT for primary insomnia compared trazodone 50 mg, zolpidem 10 mg, and placebo in 306 patients. During the first week, trazodone decreased sleep latency significantly more than placebo. Zolpidem decreased it more than either trazodone or placebo. During the second week, sleep latency effects of trazodone were comparable to placebo, while zolpidem maintained superiority. This study is frequently cited as evidence that trazodone’s sleep-onset benefit weakens over two weeks, though it continued to improve sleep maintenance.

A 2024 systematic review found additional benefits including decreased wake after sleep onset and improved objective total sleep time on polysomnography. Subjective perception of total sleep time was not significantly affected, meaning patients may not feel their sleep improved even when objective measures do.

Dosing and Timing

Standard practice for trazodone as a sleep aid:

Starting dose: 25 to 50 mg taken 30 to 60 minutes before bedtime. Taking trazodone on an empty stomach maximizes absorption speed; food delays absorption by 1 to 2 hours. For sleep-onset insomnia (trouble falling asleep), taking on an empty stomach matters more. For sleep-maintenance insomnia (waking during the night), this distinction is less critical.

Dose range for insomnia: 25 to 100 mg. The maximum commonly used dose for sleep is around 100 to 150 mg. Many prescribers avoid exceeding 100 mg in non-depressed patients.

Timing: Taking trazodone 30 minutes before bedtime is the standard starting recommendation. If it consistently takes longer than expected to produce drowsiness, taking it 1 to 2 hours before bedtime may be more effective for that patient.

Side Effects at Sleep Doses

Low-dose trazodone’s side effects are real and often unreported. The most clinically important ones:

Residual morning sedation (hangover effect). At sleep doses, trazodone’s half-life means it is largely cleared by morning. But some patients experience a 1 to 3 hour grogginess that can affect driving and early-morning cognitive tasks. A controlled study found that 50 mg trazodone produced significant impairments in short-term memory, verbal learning, equilibrium, and arm muscle endurance the morning after dosing. These effects were most pronounced during the residual sedation window.

Orthostatic hypotension. Trazodone’s alpha-1 adrenergic antagonism blunts the blood vessel constriction response that normally maintains blood pressure when standing up. The result is a blood pressure drop when moving from lying to standing, particularly in the first minutes after waking. Older adults and patients on blood pressure medications are at higher risk.

Priapism. Prolonged, painful erection unrelated to sexual arousal is a rare but serious adverse effect of trazodone, estimated at 1 in 6,000 to 1 in 10,000 male patients. It is a medical emergency requiring immediate treatment to prevent permanent erectile dysfunction. Patients should seek urgent medical attention for any erection lasting more than 4 hours.

Nausea and dizziness. More common at higher doses. Nausea often improves with continued use. Dizziness is primarily orthostatic (see above) but can also reflect vestibular effects.

Who Trazodone Is and Is Not Right For

Trazodone is frequently a reasonable option for: Patients with insomnia and comorbid depression or anxiety, where the antidepressant properties at sleep doses may provide secondary benefit. Patients who need a non-controlled sleep aid due to substance use history. Patients who cannot tolerate benzodiazepines or Z-drugs due to prior misuse or dependence. Patients in whom benzodiazepines are contraindicated (severe respiratory disease, certain neurological conditions).

Trazodone is not appropriate as first-line for: Patients whose insomnia is isolated and responds to behavioral interventions. Patients with strong CYP3A4 inhibitors in their regimen (which can significantly raise trazodone levels). Older adults, where the American Geriatrics Society Beers Criteria lists trazodone as potentially inappropriate due to fall risk and confusion. Any patient where a daytime cognitive task (driving, operating machinery) early in the morning makes next-day residual sedation unacceptable.

What Gets Missed Between Appointments

The daytime side effects of trazodone, the grogginess, the morning dizziness, the subtle cognitive fog, rarely come up in clinical appointments because patients normalize them. They attribute the grogginess to their insomnia, the dizziness to dehydration, and the cognitive slowness to getting older. The medication is not the first thing they connect.

When those effects are logged as part of a daily check-in, the pattern becomes visible. Each daytime side effect has a clinical management pathway: timing adjustments, dose reduction, or medication review. None of these options can be deployed for a side effect that was never reported.

“Trazodone side effects are among the most underreported because they happen in the morning, not at night. The medication is associated with bedtime, so patients do not connect it to what they are experiencing at 7 AM,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “Structured check-in data changes that. When I see consistent morning grogginess logged after trazodone doses, I have something actionable: try taking it earlier, try a lower dose, consider a different agent. Without that data, I am guessing.”

What Members Are Saying

RL

R.L., 46

Insomnia with Anxiety

“I had been on trazodone for six months. The sleep was better, but I was not functioning well in the mornings. I kept thinking it was my anxiety. When I logged the pattern in the app, my prescriber connected it to the trazodone timing. Taking it two hours earlier instead of 30 minutes before bed made a significant difference.”

SN

S.N., 61

Insomnia with History of Benzodiazepine Dependence

“My previous provider had avoided sleep medications completely because of my history. When I started with SiggyMD, we tried trazodone at a low dose with structured monitoring. The daily check-ins gave my prescriber confidence that it was working and that I was not developing patterns of misuse. The oversight made the whole thing safer.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

Low-dose trazodone works for sleep by blocking arousal-related receptors at concentrations too low to produce meaningful antidepressant effects. The evidence supports its use for sleep maintenance and sleep onset in the short to medium term, though the FDA has not approved it for insomnia and major sleep medicine guidelines do not recommend it as first-line.

Its advantages are real: non-controlled, inexpensive, not habit-forming, and potentially beneficial for patients whose insomnia coexists with depression or anxiety. Its side effects, particularly morning grogginess and orthostatic hypotension, are real and often unreported.

Good trazodone management means more than writing the prescription. It means knowing how the medication is affecting daily function, not just sleep. That requires data from between appointments, not summaries reconstructed at the next visit.

Start your anonymous intake with SiggyMD to get a clinically supervised treatment plan. You can also read about trazodone’s daytime side effects and which ones are clinically reportable for more detail on what to track and share with your prescriber.

Sources

• Shin JJ, Saadabadi A. Trazodone. StatPearls. NIH National Library of Medicine. Updated February 2024.

• Everitt H, et al. Trazodone for Insomnia: A Systematic Review. Innovations in Clinical Neuroscience. 2018;15(5-6):12-17.

• Roth AJ, McCall WV, Liguori A. Cognitive, Psychomotor and Polysomnographic Effects of Trazodone in Primary Insomniacs. Journal of Sleep Research. 2011;20(4):552-558.

• Kadiyala S, Chenoweth M, Watanabe JH. Off-label Policy Through the Lens of Trazodone Usage and Spending in the United States. Health Affairs Scholar. 2025;3(7).

• Psychopharmacology Institute. Trazodone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects. Accessed June 2026.

• Sateia MJ, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults. Journal of Clinical Sleep Medicine. 2017.